Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

9 treatments under study, led by Budesonideglycopyrroniumformoterol Bgf

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

100%

2 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Phase 4 (2)

Trial Status

Unknown1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT06905483Phase 4Completed

Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study

NCT03139253Phase 4Unknown

Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment

Showing all 2 trials

Research Network

Common Treatments

  • Budesonideglycopyrroniumformoterol Bgf1
  • Levofloxacin1
  • Clarithromycin1
  • Fluticasone Furoateumeclidiniumvilanterol Fuv1
  • Amoxicillin1

Active Sponsors

  • Thammasat University1
  • Yanqing Li1

Top Investigators

Related Conditions

  • Small Airway Disease1
  • Chronic Obstructive Pulmonary Disease Copd1
  • Copd1
  • Lung Function1
  • Antimicrobial Susceptibility Testing1

Activity Timeline